SEC Form 4 · accession 0001209191-17-030401
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard King
Officer — Chief Operating Officer
Period of report
May 5, 2017
Accepted (ET)
May 5, 2017 · 5:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 5, 2017 | A | 28,125 | $0.00 | A | 28,125 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $17.40 | May 5, 2017 | A | 168,750 | A | — | May 4, 2027 | Common Stock | 168,750 | 168,750 | D |
Explanation of responses
- F1Represents the grant of restricted stock units that vest 1/4th on each of June 20, 2018, June 20, 2019, June 20, 2020, and June 20, 2021.
- F2The shares subject to the option shall become vested according to the following schedule: 25% of the shares subject to the option shall vest on April 28, 2018, and the remaining shares will vest in equal monthly installments over the next 36 months.